PRINCETON, N.J., July 08, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2021 financial results on Wednesday, July 28, 2021 prior to market open.

Contract awarded for products that bring improvement to healthcare industry PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, announced its SurgiMend ® Collagen Matrix for Soft Tissue

Data Shows a Single Application of PriMatrix Closed More Wounds Than Standard of Care Alone PRINCETON, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, today announced positive clinical outcomes for

Raises Full-Year 2021 Guidance Second Quarter 2021 Highlights Revenues of $390.0 million increased 50.8% on a reported basis and 48.7% on an organic basis compared to the prior year; GAAP earnings per diluted share of $0.41, compared to $(0.00) in the second quarter of 2020; adjusted earnings per

PRINCETON, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that it is participating in the following investor conferences: On September 9, 2021, Carrie Anderson, executive vice president

PRINCETON, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2021 financial results on Tuesday, November 2, 2021, prior to the market open.

30-year healthcare and technology veteran with extensive global executive experience and diverse expertise in R&D, commercialization, product management, digital innovation and operations PRINCETON, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a

Third Quarter 2021 Highlights Revenues of $386.9 million increased 4.5% on a reported basis and 6.7% on an organic basis compared to the prior year; GAAP earnings per diluted share of $0.51, compared to $0.38 in the third quarter of 2020; adjusted earnings per diluted share of $0.86, compared to

Fourth quarter 2021 revenue is expected to be in a range of $404 million to $406 million, representing an increase of approximately 4% on a reported basis and an increase of approximately 8% on an organic basis compared to the prior year. Full-year 2021 revenue is expected to be in a range of

PRINCETON, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2021, consistent with its preliminary revenue results announced on January 11, 2022.

The Next Generation of Nerve Conduits PRINCETON, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company and pioneers in nerve repair, today announced the launch of NeuraGen ® 3D Nerve Guide Matrix , a resorbable

PRINCETON, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release first quarter 2022 financial results on Wednesday, April 27, 2022, prior to the market open. In conjunction with the earnings

PRINCETON, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2022. First Quarter 2022 Highlights Revenues of $376.6 million

PRINCETON, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- ) Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release second quarter 2022 financial results on Wednesday, July 27, 2022, prior to the market open. In conjunction with the earnings

PRINCETON, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (Nasdaq: IART), a leading global medical technology company, today announced the appointment of Renee Lo to its board of directors as an independent director to fill an existing vacancy, effective July 18,